Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

41. Effectiveness of seasonal influenza vaccination in preventing severe influenza in children: a systematic review

Effectiveness of seasonal influenza vaccination in preventing severe influenza in children: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

42. Health outcomes in offspring following exposure to maternal influenza infection in-utero: a systematic review

Health outcomes in offspring following exposure to maternal influenza infection in-utero: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

43. Systematic review and meta-analysis of the immunogenicity and reactogenicity of MF59-adjuvanted inactivated influenza vaccine among children aged <8 years

Systematic review and meta-analysis of the immunogenicity and reactogenicity of MF59-adjuvanted inactivated influenza vaccine among children aged <8 years Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

44. The use and effectiveness of oseltamivir in influenza-related respiratory infections in people with chronic cardiac and pulmonary disease: a systematic review and meta-analysis of randomized controlled trials and observational studies

The use and effectiveness of oseltamivir in influenza-related respiratory infections in people with chronic cardiac and pulmonary disease: a systematic review and meta-analysis of randomized controlled trials and observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission

2019 PROSPERO

45. Influenza and vaccination: efficacy and safety in diabetes

Influenza and vaccination: efficacy and safety in diabetes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

46. Systematic review of the cost-effectiveness of seasonal influenza vaccines in older adults

Systematic review of the cost-effectiveness of seasonal influenza vaccines in older adults Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

47. Impact of industry sponsorship on the diagnostic accuracy of rapid tests for influenza and respiratory syncytial virus: a systematic review and meta-analysis

Impact of industry sponsorship on the diagnostic accuracy of rapid tests for influenza and respiratory syncytial virus: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

48. Interventions to improve influenza vaccine coverage in children with medical comorbidities

Interventions to improve influenza vaccine coverage in children with medical comorbidities Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

49. Vaccines for preventing influenza in the frail elderly

Vaccines for preventing influenza in the frail elderly Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

50. Paediatric health outcomes following antenatal influenza vaccination and infection: protocol for a systematic review and meta-analysis

Paediatric health outcomes following antenatal influenza vaccination and infection: protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

51. Alternative dose versus standard dose of trivalent influenza vaccine for immunocompromised patients: a meta-analysis of randomized control trials

Alternative dose versus standard dose of trivalent influenza vaccine for immunocompromised patients: a meta-analysis of randomized control trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

52. Reasons for low influenza vaccine uptake in pregnant women: providers and pregnant women perspectives

Reasons for low influenza vaccine uptake in pregnant women: providers and pregnant women perspectives Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

53. Interventions to improve rates of administration of seasonal influenza vaccine by health care providers: a systematic review and meta-analysis

Interventions to improve rates of administration of seasonal influenza vaccine by health care providers: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

54. Baloxavir marboxil (Xofluza) - For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours

Baloxavir marboxil (Xofluza) - For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil) Company: Shionogi, Inc. Application Number: 210854 Approval Date: 10/24/2018 Persons with disabilities having problems accessing the PDF

2018 FDA - Drug Approval Package

55. Update: Can Newer Rapid Influenza Tests Rule Out Disease?

Update: Can Newer Rapid Influenza Tests Rule Out Disease? TAKE-HOME MESSAGE Although newer rapid in?uenza tests have improved our ability to rule out disease, they are still better at ruling in in?uenza. Change in management should be considered before testing. Update: Can Newer Rapid In?uenza Tests Rule Out Disease? EBEM Commentators Katie Pettit, MD Julie L. Welch, MD Department of Emergency Medicine Indiana University School of Medicine Indianapolis, IN Results Pooled diagnostic accuracy

2018 Annals of Emergency Medicine Systematic Review Snapshots

56. Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza

Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza - ACOG Menu ▼ Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza Page Navigation ▼ Number 753 Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group The Society for Maternal-Fetal Medicine endorses this document. This Committee Opinion was developed by the American College (...) with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product. Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza ABSTRACT: Pregnant and postpartum women are at high risk of serious complications of seasonal and pandemic

2018 American College of Obstetricians and Gynecologists

57. The use of antiviral drugs for influenza: Guidance for practitioners

The use of antiviral drugs for influenza: Guidance for practitioners This practice point summarizes the use of antiviral drugs to manage influenza illness in children and youth. Recommendations are based on previously published Canadian recommendations for clinicians on the use of antiviral drugs to prevent and treat influenza. Detailed information on the selective use of chemoprophylaxis can be found in the original document, which also highlights the importance of secondary bacterial (...) infections (i.e., Streptococcus pneumoniae , methicillin-sensitive  Staphylococcus aureus and methicillin-resistant  S. aureus ) in cases of severe influenza illness. This document serves as a reference for all clinicians while providing general principles and a user-friendly flow diagram to assist decision-making. Keywords : Antiviral therapy; Children; Influenza; Neuraminidase inhibitors

2018 Canadian Paediatric Society

58. Vaccine recommendations for children and youth for the 2018/2019 influenza season

Vaccine recommendations for children and youth for the 2018/2019 influenza season The Canadian Paediatric Society continues to encourage annual influenza vaccination for ALL children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2018/2019 influenza season are not substantially changed from those of last season. Quadrivalent vaccine, if available, is recommended for children 6 months to 17 years of age. Either inactivated (...) influenza vaccine or live attenuated influenza vaccine may be used for children and youth 2 to 17 years of age who are not immunocompromised. Keywords:   Children; Influenza vaccine; Inactivated influenza vaccine; LAIV; NACI

2018 Canadian Paediatric Society

59. VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B

VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B Haute Autorité de Santé - VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les (...) Médicaments VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Substance active (DCI) vaccin diphtérique, tétanique, coquelucheux (acellulaire, multicomposé), de l'hépatite B (ADNr), poliomyélitique (inactivé) et conjugué de l'Haemophilus de type b (adsorbé) INFECTIOLOGIE - Nouveau médicament Nature de la demande Inscription Avis de la CT du 11 octobre 2017 Pas d’avantage clinique démontré pour la primovaccination et le

2018 Haute Autorite de sante

60. VAXIGRIPTETRA, tetravalent vaccine against seasonal influenza

VAXIGRIPTETRA, tetravalent vaccine against seasonal influenza Haute Autorité de Santé - VAXIGRIPTETRA, vaccin quadrivalent contre la grippe saisonnière Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments VAXIGRIPTETRA, vaccin quadrivalent contre la grippe saisonnière Substance active (DCI) vaccin grippal quadrivalent, inactivé, à virion

2018 Haute Autorite de sante